Deep inside your liver cells, a protein called SREBP-1c acts as the master switch for de novo lipogenesis¹¹ de novo lipogenesis
De novo lipogenesis: the biochemical process by which the liver converts carbohydrates into fatty acids and triglycerides for storage. Under normal conditions, insulin turns this switch on after meals — signaling the liver to convert surplus glucose into fat. The rs11868035 variant in the SREBF1 gene alters the regulation of this switch, tipping carriers toward higher triglyceride synthesis, impaired insulin signaling, and a modestly elevated risk of type 2 diabetes.

The Mechanism

SREBF1 (Sterol Regulatory Element Binding Transcription Factor 1) encodes two isoforms from the same locus through alternative promoter usage: SREBP-1a (a broadly expressed, potent transactivator) and SREBP-1c (the liver- and fat-tissue-dominant form that is the primary target of insulin signaling). rs11868035 sits in the 3' UTR and intronic regions of SREBF1, where variants can influence mRNA stability, splicing efficiency, and ultimately protein expression levels of SREBP-1c.

SREBP-1c is synthesized as an inactive precursor anchored to the endoplasmic reticulum. When insulin rises after a meal, the PI3K/Akt pathway triggers its proteolytic cleavage, allowing the mature SREBP-1c fragment to enter the nucleus and activate transcription of lipogenic genes — including fatty acid synthase (FASN), acetyl-CoA carboxylase (ACC), and stearoyl-CoA desaturase (SCD1). The rs11868035 risk variant is associated with altered SREBP-1c activity, promoting greater hepatic fat synthesis and contributing to the insulin-resistance cycle: excess hepatic lipid accumulation impairs insulin receptor signaling, further dysregulating glucose and lipid homeostasis.

The Evidence

The most robust human evidence comes from a 15,734-subject Danish cohort study²² 15,734-subject Danish cohort study
Grarup N et al. Diabetes 2008 that linked the minor alleles of rs11868035 and two co-inherited variants (rs2297508, rs1889018; R²=0.6–0.8) to a modestly elevated T2DM risk. For the best-characterized linked variant rs2297508, the per-allele OR for diabetes was 1.17 (95% CI 1.05–1.30, p=0.003); meta-analysis across an additional cohort produced OR 1.08 per allele (p=0.001). Crucially, the risk alleles also associated with elevated plasma glucose at 30 and 120 minutes³³ elevated plasma glucose at 30 and 120 minutes
and elevated serum insulin at 120 min during oral glucose tolerance testing (p<0.006), pointing to impaired glucose clearance rather than fasting hyperglycemia alone.

A Chinese cohort study⁴⁴ Chinese cohort study
Liu JX et al. Diabetes Res Clin Pract 2008 of 327 subjects found significant differences in rs11868035 genotype and allele distributions between T2DM patients and controls (p=0.013 and p=0.001 respectively), and the risk allele was associated with higher LDL cholesterol — consistent with SREBP-1c's role in both triglyceride and cholesterol synthesis. This finding was replicated across a larger 1,141-subject Han and Dongxiang Chinese cohort⁵⁵ 1,141-subject Han and Dongxiang Chinese cohort
Liu JX et al. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2012 where the risk allele was identified as a T2DM risk factor in both ethnic groups.

For liver health, a liver stiffness study⁶⁶ liver stiffness study
Müller M et al. Int J Mol Sci 2013 found that risk-allele carriers had significantly higher liver stiffness scores (p=0.029), and the combined effect of carrying both the SREBP1c and PNPLA3 risk genotypes produced substantially greater liver stiffness (p=0.005), suggesting a synergistic lipogenic pathway.

A triglyceride link emerged from a Chinese NAFLD study⁷⁷ Chinese NAFLD study
Peng XE et al. Sci Rep 2016 where the G allele (protective genotype on plus strand) was associated with lower triglyceride levels in healthy controls (p<0.01), and from a Mexican ACS cohort⁸⁸ Mexican ACS cohort
Vargas-Alarcón G et al. PLoS One 2019 showing significant association between rs11868035 and plasma triglyceride levels.

A pharmacogenomics study in 157 schizophrenia patients⁹⁹ 157 schizophrenia patients
Vassas TJ et al. Pharmacogenomics 2014 found that risk-allele carriers had significantly elevated total cholesterol (p=0.01), LDL (p=0.03), and triglycerides (p=0.04) despite statin therapy, suggesting the variant may attenuate statin efficacy — an important clinical consideration.

Practical Actions

The SREBP-1c pathway is acutely responsive to dietary carbohydrate load. Because SREBP-1c is the primary executor of insulin-stimulated lipogenesis, carriers of the risk allele benefit most from strategies that reduce postprandial insulin spikes: limiting refined carbohydrates and added sugars directly curtails the insulin signal that activates SREBP-1c. Monitoring fasting triglycerides and non-HDL cholesterol provides a lipid-specific window into SREBP-1c activity. HbA1c monitoring tracks the slower trajectory toward glucose dysregulation.

The statin-interaction finding warrants attention: if lipid control is inadequate on standard statin doses, the rs11868035 variant may be contributing — a conversation worth having with the prescribing physician.

Interactions

rs11868035 sits in the same lipogenic pathway as PNPLA3 (rs738409), a hepatic lipase variant strongly linked to NAFLD and liver fibrosis. The Müller 2013 study demonstrated that carriers of both variants showed substantially greater liver stiffness than carriers of either alone, suggesting a compound lipogenic burden. This interaction is a strong candidate for a compound action.

Within the SREBP-1c regulatory network, insulin receptor signaling variants (ENPP1 rs1044498, IRS-1 rs2943641) upstream of SREBP-1c activation can compound the downstream lipogenic dysregulation associated with rs11868035.

Your skin is not just a passive envelope — it is an active immune barrier, and filaggrin is one of its most critical structural proteins. FLG (filaggrin) is produced in huge quantities in the outermost layers of the epidermis, where it aggregates keratin filaments¹¹ aggregates keratin filaments
Filaggrin cross-links the keratin cytoskeleton into the dense protein mesh that gives the cornified envelope its mechanical strength and is then enzymatically broken down into natural moisturizing factor (NMF) — the collection of amino acids and derivatives that keeps the stratum corneum hydrated and acidic. The rs12123821 variant lies in the regulatory region of the FLG locus on chromosome 1q21, and the T allele tags a haplotype associated with reduced filaggrin expression. When filaggrin is in short supply, the skin barrier leaks.

The Mechanism

A well-functioning filaggrin layer does two things simultaneously: it locks water in and keeps allergens and microorganisms out. FLG variants that reduce filaggrin expression disrupt both functions in parallel. Transepidermal water loss (TEWL²² TEWL
A standardized measurement of water vapor flux through the skin surface; elevated TEWL means the barrier is leaking water and is correspondingly more permeable to external insults) rises measurably in FLG variant carriers even before any visible eczema appears. At the same time, the disrupted tight junction zone allows environmental allergens — house dust mite proteins, pollen fragments, pet dander, food proteins — to breach the stratum corneum and encounter cutaneous dendritic cells in a pro-inflammatory context rather than the tolerogenic context of the gut. This epicutaneous sensitization route³³ epicutaneous sensitization route
Allergen encountered through the skin primes a TH2 immune response, whereas the same allergen ingested orally typically promotes tolerance is now understood as the primary mechanism initiating the atopic cascade.

The rs12123821 T allele is a common, low-frequency variant (about 4.8% in Europeans, essentially absent in East Asians) that tags this reduced-expression haplotype. Unlike the rare high-penetrance FLG loss-of-function coding mutations (R501X, 2282del4) that completely abolish filaggrin production, rs12123821 represents a more moderate graded impairment — contributing to population-level eczema risk with a well-powered OR of 1.40 in the largest available study.

The Evidence

The primary evidence comes from the largest atopic dermatitis GWAS meta-analysis published to date. Budu-Aggrey et al. (Nature Communications, 2023)⁴⁴ Budu-Aggrey et al. (Nature Communications, 2023)
European and multi-ancestry GWAS meta-analysis of atopic dermatitis highlights importance of systemic immune regulation; Ashley Budu-Aggrey et al., Nat Commun 14:6172, 2023 assembled a discovery cohort of 1,086,394 individuals across 29 studies and a replication cohort of over 3.6 million through 23andMe. At the FLG locus, rs12123821 reached OR=1.40 (95% CI 1.35–1.45, P=4.05×10⁻⁹⁰) in European discovery and OR=1.27 (P=1.4×10⁻²²⁸) in the 23andMe replication — some of the most statistically robust findings in complex disease genetics. A total of 91 AD loci were identified; the FLG region remained the single largest common-variant effect.

The mechanistic link was established in the landmark Palmer et al. (Nature Genetics, 2006)⁵⁵ Palmer et al. (Nature Genetics, 2006)
Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis; CA Palmer, IJ McLean et al., Nat Genet 38(4):441–446 study, which showed filaggrin variants "establish a key role for impaired skin barrier function in the development of atopic disease" and that approximately 9% of Europeans carry a FLG loss-of-function allele. Subsequent infant cohort studies quantified the early timeline: Flohr et al. (2011)⁶⁶ Flohr et al. (2011) showed FLG variant carriers already had substantially elevated TEWL (21.59 vs 11.24 g m⁻² h⁻¹) and 4.26-fold eczema odds at just 3 months of age, and the PreventADALL cohort (2022)⁷⁷ PreventADALL cohort (2022) (1,836 infants) confirmed OR=2.89 for early eczema onset. The downstream consequence reaches beyond eczema: the Venkataraman et al. (2014)⁸⁸ Venkataraman et al. (2014) Isle of Wight cohort demonstrated that FLG loss-of-function mutations carry striking food allergy risk (OR=31.46 at age 10), mediated entirely through the prior eczema state and epicutaneous sensitization.

Practical Actions

The core strategy for FLG variant carriers has two components: reinforcing the deficient barrier from outside, and reducing exposure to triggers that exploit the barrier gap. High-lipid emollients — particularly those formulated with ceramides, the lipid class that fills the intercellular spaces of the stratum corneum — can partially compensate for reduced filaggrin-derived NMF. Frequency and coverage matter: casual daily moisturizing is not equivalent to therapeutic barrier maintenance. Environmental allergen mitigation (house dust mite covers, avoidance of certain preservatives such as methylisothiazolinone in skincare products) is particularly valuable for FLG variant carriers because their barrier lets these sensitizers through more readily. Proactively managing known eczema flare triggers — rather than reacting after the fact — is the evidence-based posture for this genotype.

Interactions

FLG variant status interacts with environmental allergen burden: the same FLG haplotype that increases eczema risk in a high-allergen household may have attenuated effects in a lower-allergen environment, suggesting that allergen exposure amplifies the genetic risk. Within the atopic cascade, rs12123821 T-allele carriers who develop eczema early face substantially higher risk for subsequent asthma and food allergy compared to individuals whose eczema has non-FLG genetic drivers — because FLG-driven eczema specifically creates the epicutaneous sensitization route. Related FLG locus variants rs61816761 and rs558269137 encode the classical high-penetrance loss-of-function coding mutations (R501X and 2282del4) with larger individual effect sizes but much lower population frequencies; rs12123821 captures additional population-level risk at the same locus via regulatory architecture.

Cholesteryl ester transfer protein (CETP) is the molecular shuttle that remodels your lipoprotein particles. Operating in blood plasma, it exchanges cholesteryl esters¹¹ cholesteryl esters
lipid molecules in which cholesterol is esterified with a fatty acid — the main cargo form of cholesterol inside lipoprotein particles from HDL particles for triglycerides from VLDL and LDL. The net effect: each CETP transaction depletes HDL of cholesterol and returns that cholesterol to the atherogenic lipoprotein pool. More CETP activity means lower HDL-C; less activity means higher HDL-C.

rs12447924 is a C/T variant located approximately 1,700 bases upstream of the CETP transcription start site, within the gene's promoter region. It sits in a tightly linked haplotype block along with rs3764261 (−2568), the GWAS lead SNP for this region, and rs4783961 (−998), three tagSNPs in strong linkage disequilibrium (D′=0.92–0.97) that collectively mark one of the most replicated HDL-cholesterol loci in the human genome. The T allele at rs12447924 is part of the HDL-raising 'ATAA' promoter haplotype; the C allele marks the HDL-lowering 'CTAG' haplotype.

The Mechanism

Upstream variants in this haplotype block regulate CETP transcription in the liver. The HDL-raising haplotype — tagged by the T allele at rs12447924 — is associated with reduced CETP gene expression and lower plasma CETP activity. With less CETP protein secreted, the rate of cholesteryl ester transfer from HDL to VLDL slows, allowing HDL particles to retain more of their cholesterol cargo and circulate at higher concentrations.

The promoter haplotype containing the C allele at rs12447924 is associated with normal-to-higher CETP expression, maintaining the full cholesterol transfer rate and producing lower circulating HDL-C. Mechanistic studies examining adjacent upstream variants (rs247616, in near-complete LD with this block) confirm that these upstream elements act as transcriptional enhancers in hepatocytes: the minor-frequency variants reduce luciferase reporter activity by approximately 1.7-fold in HepG2 cells²² 1.7-fold in HepG2 cells
Chasidah Oommen et al., Regulation of CETP expression by upstream polymorphisms, Atherosclerosis 2015. This directly links the promoter haplotype to the amount of CETP protein produced, not just its enzymatic activity per molecule.

The Evidence

The most detailed genotype-level data for rs12447924 comes from the Sikh Diabetes Study³³ Sikh Diabetes Study
Wander et al., n=2,431 individuals stratified by glycemic status, where haplotype analysis showed the ATAA haplotype (T allele at rs12447924) associated with +2.71 mg/dL higher HDL-C (p=6.38×10⁻⁵) in normoglycemic individuals, and the CTAG haplotype (C allele at rs12447924) associated with −1.78 mg/dL lower HDL-C (p=0.025).

Because rs12447924 is in strong LD with the GWAS lead SNPs for this region, studies of those neighboring variants provide the broadest evidence base. The Women's Health Study⁴⁴ Women's Health Study
Ridker et al., n=18,245, average 10-year follow-up found that CETP haplotype variants in this block were associated with 3.1 mg/dL higher HDL-C and a 24% lower risk of myocardial infarction (HR 0.76, 95% CI 0.62–0.94). A genome-wide meta-analysis of statin response⁵⁵ genome-wide meta-analysis of statin response
Postmus et al., n=27,720 found the CETP locus to be the only genome-wide significant predictor of HDL-C increase during statin treatment, with the HDL-raising haplotype predicting a greater HDL response to statins.

The gene-diet interaction evidence is clinically meaningful. In the combined POUNDS LOST and DIRECT randomized trials⁶⁶ POUNDS LOST and DIRECT randomized trials
Ma et al., n=894 total, individuals carrying the CETP upstream haplotype in the HDL-lowering direction showed significantly smaller HDL-C improvements on low-fat diets compared to high-fat diets (11.7 vs 4.5% increase, p<0.001). The SNAP trial⁷⁷ SNAP trial
Economos et al., n=524 young adults further showed that the HDL-lowering CETP genotype predicted declining HDL-C over time in the untreated control arm, but this trajectory was eliminated in the lifestyle intervention arm — demonstrating that the genetic disadvantage is modifiable.

Practical Actions

For TT homozygotes (~58% of Europeans): your CETP promoter is biased toward the HDL-raising haplotype. HDL-C levels are expected to be in the upper range for your demographic. Standard lipid monitoring applies.

For CT heterozygotes (~36% of Europeans): one C allele places you in an intermediate position. HDL-C may trend slightly lower than TT individuals. Limiting saturated fat intake and maintaining a healthy omega-3 to omega-6 ratio preserves your HDL level.

For CC homozygotes (~6% of Europeans): two C alleles orient your CETP promoter toward full expression and maximum cholesteryl ester transfer rate. HDL-C is expected to be below-average. The gene-diet evidence specifically supports choosing higher dietary fat quality (replacing saturated fat with polyunsaturated fats) over a low-fat approach when managing HDL. Checking both HDL-C and ApoA-I gives a more complete cardiovascular picture than HDL-C alone.

Interactions

rs12447924 is in strong linkage disequilibrium (D′=0.92–0.97) with rs3764261, the GWAS lead SNP for the CETP upstream haplotype block, and with rs247616, the variant most directly implicated in transcriptional regulation. Genetic tests may report any of these three; they largely tag the same underlying haplotype effect. rs708272 (TaqIB, intron 1) is in the same gene but a different LD block — it adds independent HDL-C variance on top of the upstream haplotype.

The LIPC rs1532085 variant also modulates HDL-C levels through hepatic lipase activity rather than CETP-mediated transfer. When both a CETP upstream C-allele genotype and a LIPC A-allele genotype co-occur, the two mechanisms partially counteract each other: reduced CETP activity (LIPC A allele, fewer transfers) tends to raise HDL, while the CETP C-allele haplotype tends to lower it. The net HDL-C level depends on which effect predominates, and particle-level testing (NMR lipoprofile) is more informative than total HDL-C in individuals carrying both variants.

CYP3A4 is the most abundant drug-metabolizing enzyme in the human liver, responsible for the biotransformation of approximately 50% of all clinically used medications¹¹ 50% of all clinically used medications
Including statins, immunosuppressants, calcium channel blockers, benzodiazepines, chemotherapy agents, and many antibiotics. The CYP3A4*16B haplotype, defined primarily by the rs12721629 variant, carries a missense substitution (Thr185Ser in older literature numbering; p.Leu373Val in current HGVS notation using transcript NM_017460.6) that alters the enzyme's active site geometry in a way that affects different drug substrates to different degrees.

This variant is largely confined to Japanese and broader East Asian populations, where heterozygous carriers appear in roughly 3-4% of individuals. In European, African, and South Asian populations it is essentially absent. The CYP3A4 gene itself sits on the minus strand of chromosome 7, so the coding-strand change (c.554C>G in older transcript notation, c.1117C>G in NM_017460.6) is reported on the plus strand as G>C at chromosomal position 99,762,177 (GRCh38).

The Mechanism

The Thr185Ser substitution (threonine-to-serine at position 185 in the older protein numbering) changes a hydroxyl-bearing residue in the substrate-binding channel of CYP3A4. In vitro studies using recombinant enzyme²² In vitro studies using recombinant enzyme
CYP3A4*16 expressed in Sf21 insect cells co-expressing human NADPH-P450 reductase revealed that the effect is strikingly substrate-dependent: intrinsic clearance of midazolam (a standard CYP3A4 probe) fell by about 50% for the primary 1'-hydroxylation pathway and 30% for 4-hydroxylation, while carbamazepine epoxidation dropped by 74%. This contrast with, for example, CYP3A4*22, which reduces enzyme expression uniformly across substrates, suggests the *16B substitution changes the substrate access channel geometry rather than overall protein stability or expression.

The kinetic mechanism differs by substrate. For midazolam, the variant shows elevated Km (reduced binding affinity) with lower Vmax. For carbamazepine, the changes are more complex and consistent with a distorted two-site cooperative binding model, suggesting the variant may disrupt allosteric activation normally seen with this substrate.

The Evidence

The most clinically informative data comes from two studies in Japanese cancer patients. Sai et al. examined 235 patients³³ Sai et al. examined 235 patients
paclitaxel pharmacokinetics measured in 229 with usable plasma samples receiving paclitaxel chemotherapy and identified eight *16B carriers (all heterozygotes). Carriers showed a 20% lower median AUC ratio for the 3'-p-hydroxylation metabolite and a 2.4-fold higher ratio for the 6α-hydroxylation product (P<0.001), indicating that CYP3A4*16B shifts paclitaxel metabolism away from the 3'-p-hydroxylation route toward the 6α-hydroxylation route — with potential consequences for drug efficacy and metabolite toxicity profiles.

Sai et al. studied 177 Japanese cancer patients⁴⁴ Sai et al. studied 177 Japanese cancer patients
Irinotecan pharmacokinetics with CYP3A4 haplotype analysis receiving irinotecan and found that male patients carrying *16B had approximately 50% lower APC/irinotecan ratios, indicating significantly reduced CYP3A4-mediated oxidative metabolism of this anticancer drug. No female *16B carriers were enrolled. Although overall irinotecan total clearance was not significantly different between genotypes — suggesting compensatory pathways — the altered metabolite ratios could affect the balance between efficacy and toxicity (the APC pathway is thought to be a detoxification route).

Maekawa et al.⁵⁵ Maekawa et al.
Kinetic characterization of CYP3A4.16 in insect cell microsomes provided the mechanistic foundation: recombinant CYP3A4*16 shows 50% reduced intrinsic clearance for midazolam 1'-hydroxylation, 30% for midazolam 4-hydroxylation, and 74% for carbamazepine 10,11-epoxide formation, confirming that the magnitude of impairment varies considerably by substrate.

CYP3A4*16B is not included in current CPIC or DPWG clinical guidelines, which focus on CYP3A4*22 (rs35599367) and the CYP3A5 *1/*3 system (rs776746) as the established pharmacogenomic variants for CYP3A4 pathway guidance. The rarity of *16B outside East Asian populations limits the evidence base for formal guideline development.

Practical Actions

Because CYP3A4*16B is heterozygous in virtually all carriers and causes moderate, substrate-dependent activity reduction, the clinical impact depends heavily on which drugs you take. For chemotherapy drugs like paclitaxel and irinotecan, the altered metabolite ratios could affect both efficacy and the toxicity profile — oncologists should be aware that standard dosing may produce different metabolite distributions in *16B carriers. For drugs with narrow therapeutic windows (carbamazepine, tacrolimus), the 50-74% reduction in intrinsic clearance observed in vitro suggests that doses appropriate for normal CYP3A4 metabolizers may need adjustment.

The absence of CYP3A4*16B from clinical pharmacogenomic panels used in Western countries means carriers are unlikely to receive a pharmacogenomic alert for this specific variant. East Asian patients undergoing comprehensive pharmacogenomic testing may benefit from inclusion of this variant.

Interactions

CYP3A4*16B's effects are additive with other reduced-function CYP3A variants. Individuals of East Asian ancestry who carry both CYP3A4*16B and CYP3A5*3/*3 (rs776746 CC, the most common genotype globally) would have reduced function in both CYP3A enzymes, potentially reaching total CYP3A activity levels comparable to carriers of CYP3A4*22 in European populations.

The substrate-dependent nature of *16B also means that drug-drug interactions can produce unpredictable results. A CYP3A4 inhibitor like itraconazole that uniformly blocks enzyme activity may have a larger relative impact on carbamazepine (already 74% reduced) than on midazolam (50% reduced) in *16B carriers, since both baseline activities start from a lower point. Conversely, inducers like rifampin may partially rescue activity in *16B by upregulating enzyme expression to compensate for per-molecule inefficiency.

The CYP3A4*22 variant (rs35599367) is a separate, more common, and better-studied reduced-function allele that should be tested alongside *16B in East Asian patients receiving narrow therapeutic index CYP3A4 substrates.

The PER3 gene¹¹ PER3 gene
Period Circadian Regulator 3, one of the three Period proteins forming the negative feedback arm of the molecular circadian clock encodes a protein that accumulates during the day, translocates into the nucleus, and represses the CLOCK-BMAL1 transcription complex that drove its own synthesis — completing one full oscillation every ~24 hours. The rs139315125 variant introduces an arginine at position 417 where histidine normally sits, and it almost always arrives in combination with the rs150812083 Pro415Ala change, seven base pairs upstream on the same chromosome copy.

On its own, H417R is classified as conflicting significance in ClinVar — most recent submissions rate it as uncertain or likely benign, reflecting the difficulty of deconvolving individual contributions when the two changes always co-occur. Its primary clinical importance is as the second component of the compound P415A/H417R haplotype that causes familial advanced sleep phase syndrome 3 (FASPS3)²² familial advanced sleep phase syndrome 3 (FASPS3)
An autosomal dominant circadian rhythm disorder characterized by sleep onset 4-6 hours earlier than population average, with spontaneous waking around 4 AM, and associated seasonal mood vulnerability.

The Mechanism

PER3 protein stability depends critically on the local structure of its PAS domain³³ PAS domain
PER-ARNT-SIM domain — a conserved protein-protein interaction module shared across clock proteins, used by PER proteins to dimerize and interact with CRY repressor partners. At position 417, histidine contributes to the hydrogen-bonding network that stabilizes this domain. The G allele substitutes the positively charged, bulkier arginine, perturbing the local fold and — when combined with the adjacent Pro415Ala substitution — produces a protein that degrades faster and accumulates to lower nuclear concentrations despite elevated mRNA production.

Zhang et al. (PNAS, 2016)⁴⁴ Zhang et al. (PNAS, 2016)
Zhang L et al. A PERIOD3 variant causes a circadian phenotype and is associated with a seasonal mood trait. PNAS 113(11):E1536-44. showed that PER3-P415A/H417R has reduced transcriptional repressor activity across multiple titers compared with wild-type PER3, and loses the ability to stabilize both PER1 and PER2 — compounding the clock acceleration. Transgenic mice expressing the compound human allele showed altered circadian period under constant light conditions and depression-like behavior under short photoperiod, directly linking the destabilized PER3 to seasonal affective phenotypes.

The Evidence

The P415A/H417R compound haplotype was characterized in a three-generation family with FASPS3 by Zhang et al. (PNAS 2016, PMID 26903630). Affected members fell asleep by midnight and woke spontaneously by 8:15 AM (~4 hours earlier than average), and scored at the 97th–99th percentile for seasonal mood variation with worst symptoms in December and January. All published functional studies tested the two substitutions together; the individual contribution of H417R alone was not deconvolved, which explains the conflicting ClinVar classifications.

At the population level, the G allele of rs139315125 is rare: ~0.58% in Europeans, ~0.04% in Africans, and ~0.005% in East Asians (gnomAD exomes). Given the near- perfect co-occurrence with rs150812083 G on the same chromosome, allele frequencies and phenotypic associations are effectively shared between the two entries. The Jones et al. 2019 GWAS (Nature Communications, 697,828 individuals) identified the PER3 locus as contributing to extreme morningness chronotype with an odds ratio of 1.44, and objective sleep timing ~8 minutes earlier by actigraphy.

ClinVar accession VCV000242411 currently reflects conflicting classifications (1 pathogenic, 2 uncertain significance, 1 likely benign), with the pathogenic call resting on co-segregation in the FASPS3 family; the uncertain and likely benign calls reflect the difficulty of attributing causality to one variant when it always co-occurs with a second.

Practical Implications

Carriers of this variant who do not also carry the rs150812083 G allele face genuinely uncertain phenotypic impact — the functional evidence is for the compound haplotype. Carriers who are positive at both positions have a biologically accelerated clock: an intrinsic circadian period shorter than 24 hours that advances the entire sleep-wake cycle. The degree of phase advance varies with environment and other genetic modifiers, but the affected FASPS3 family consistently showed 4-hour advances.

Evening bright light therapy — exposure between 7 and 9 PM — is the most evidence-supported intervention for advanced sleep phase. Light in this window falls in the phase-delay zone of the circadian phase response curve⁵⁵ circadian phase response curve
The PRC describes how light exposure at different clock times shifts the circadian oscillator; late-evening light delays the clock, early-morning light advances it, counteracting the pathological advance. Avoiding bright light in the first hour after waking prevents compounding the phase shift further.

Interactions

rs139315125 (H417R) and rs150812083 (Pro415Ala) sit seven base pairs apart and are almost always inherited together on the same chromosome as the FASPS3 compound haplotype. Functionally, both changes contribute to PER3 protein destabilization; the compound state produces more severe clock acceleration than either change alone based on current evidence.

The same circadian feedback loop involves rs228697 (PER3 Pro864Ala), which lengthens circadian period (evening-shifting) rather than shortening it. An individual carrying both an evening-shifting PER3 variant and this morning- advancing haplotype would experience opposing molecular forces, potentially producing an unstable or irregular circadian rhythm. rs35333999 (PER2 V903I) is another evening-shifting component in the same repressor complex.

The seasonal mood dimension creates a plausible interaction with melatonin pathway variants, particularly rs10830963 (MTNR1B), though no published study has formally characterized compound H417R/MTNR1B carriers.

Every cell in the small intestine and kidney proximal tubule faces a fundamental challenge: cationic amino acids — lysine, arginine, and ornithine¹¹ lysine, arginine, and ornithine
These positively charged (cationic) amino acids are essential for protein synthesis, urea cycle function, and nitric oxide production. They share a common transporter because of their similar charge and size properties — must be absorbed across the basolateral membrane and returned to the bloodstream. SLC7A7 encodes y+LAT1, the catalytic subunit of the heterodimeric transporter that performs this export step. When both copies of SLC7A7 are disrupted, cationic amino acids become trapped inside intestinal and renal tubular cells, never reaching the bloodstream in meaningful quantities after meals. The result is lysinuric protein intolerance (LPI)²² lysinuric protein intolerance (LPI)
OMIM #222700 — autosomal recessive aminoaciduria; Finnish prevalence 1:60,000; worldwide approximately 200 documented cases.

The c.895-2A>T change (NM_003982.4) obliterates the acceptor splice site at the 5′ end of exon 7 of SLC7A7. Because SLC7A7 is transcribed from the minus strand of chromosome 14, the plus-strand (genome file) change is T>A at position 22,775,938. In Finnish patients, this single mutation accounts for essentially all LPI cases — a founder effect from a single ancestral carrier whose descendants spread through the Finnish population over centuries. In the rest of the world, LPI arises from compound heterozygosity among the ~60 known pathogenic SLC7A7 variants; c.895-2A>T is rare outside Finland.

The Mechanism

The c.895-2A>T transversion converts the invariant AG of the intron 6 splice acceptor consensus to TG. Spliceosomes cannot recognize this disrupted consensus, and normal exon 7 inclusion is abolished. The aberrant splicing creates a 10-bp deletion at the start of exon 7, shifting the reading frame and generating a premature stop codon 26 codons downstream. The truncated y+LAT1 protein retains no residual transport activity and is retained intracellularly rather than trafficking to the plasma membrane — a complete loss of function.

Without functional y+LAT1 at the basolateral membrane, cationic amino acids accumulate in intestinal epithelial cells and are excreted in urine rather than reabsorbed. Plasma lysine, arginine, and ornithine fall chronically low. Arginine deficit impairs urea cycle function, causing postprandial hyperammonemia³³ postprandial hyperammonemia
Ammonia normally converted to urea via the ornithine-citrulline-arginine cycle cannot proceed efficiently when ornithine and arginine are deficient; citrulline supplementation bypasses this block by providing a urea-cycle intermediate via a neutral amino acid transporter that is not affected by the SLC7A7 defect. Intracellular arginine trapping also drives excessive nitric oxide (NO) synthesis, which Mannucci et al.⁴⁴ Mannucci et al.
Mannucci et al., J Inherit Metab Dis, 2005 — elevated plasma nitrate and enhanced nitrite production from LPI fibroblasts propose as a unifying mechanism for the diverse multi-organ complications of LPI.

The Evidence

LPI was recognised as a distinct genetic disease in Finland in the 1960s, but its molecular basis remained unknown until 1999, when two groups simultaneously identified SLC7A7 mutations as the cause. Torrents et al.⁵⁵ Torrents et al.
Torrents et al., Nature Genetics, 1999 — identified the gene encoding y+LAT1; confirmed transport abolition in Xenopus oocyte functional assay showed that the Finnish founder allele completely abolished transport of cationic amino acids when expressed in Xenopus oocytes with the heavy chain partner 4F2hc.

Sperandeo et al.⁶⁶ Sperandeo et al.
Sperandeo et al., Human Mutation, 2008 — comprehensive mutation analysis, 130 patients, ≥98 families, 43 distinct variants described 43 distinct pathogenic SLC7A7 variants and confirmed that c.895-2A>T is the sole founder allele in Finland. Despite sharing the same homozygous genotype, Finnish LPI patients show extreme phenotypic variability — ranging from mild growth failure to life-threatening pulmonary alveolar proteinosis — with no genotype-phenotype correlation.

Tringham et al.⁷⁷ Tringham et al.
Tringham et al., Mol Genet Metab, 2012 — genome-wide microarray in Finnish LPI patients vs controls; 926 differentially expressed genes used genome-wide microarray analysis to show that the Finnish founder mutation triggers widespread secondary transcriptional dysregulation — 926 differentially expressed genes enriched in inflammatory response, immune system processes, and apoptosis pathways. This explains why LPI is far more complex than a simple amino acid transport defect.

Multi-organ complications are well characterised from long-term Finnish cohort data: pulmonary alveolar proteinosis occurs in a significant subset and can be fatal; renal disease including immune complex-mediated glomerulonephritis and proximal tubular dysfunction develops over decades; hemophagocytic lymphohistiocytosis/macrophage activation syndrome is a recognized life-threatening complication; and autoimmune manifestations including lupus-like disease have been reported. Parto et al.⁸⁸ Parto et al.
Parto et al., Human Pathology, 1994 — autopsy findings in 4 Finnish pediatric LPI fatalities documented pulmonary alveolar proteinosis, immune complex glomerulonephritis, hepatic dysfunction, and amyloid deposits across all four cases.

Practical Actions

For confirmed homozygous individuals, management is lifelong and requires a metabolic specialist. The two pillars are:

1. Dietary protein restriction (0.8–1.5 g/kg/day in children; 0.5–0.8 g/kg/day in adults) to limit the postprandial cationic amino acid load that cannot be handled by deficient y+LAT1.

2. Oral citrulline supplementation (≤100 mg/kg/day in 4 divided doses) — citrulline is a neutral amino acid transported by intact systems, bypassing the y+LAT1 defect. It replenishes the urea cycle's ornithine supply, normalising ammonia clearance after meals and permitting modestly higher protein intake.

L-lysine-HCl (20–30 mg/kg/day) can partially correct lysine deficiency but does not address arginine or ornithine. Carnitine (25–50 mg/kg/day) is added when hypocarnitinemia is documented. Nitrogen-scavenger drugs (sodium benzoate, sodium phenylacetate) are used for acute hyperammonemic crises alongside IV arginine and dextrose.

Carriers (one copy) are clinically and biochemically normal; no dietary restrictions or treatment is needed.

Interactions

Compound heterozygotes carrying c.895-2A>T on one chromosome and a different pathogenic SLC7A7 variant on the other also develop full LPI. Because the Finnish founder allele is rare outside Finland, non-Finnish LPI patients are typically compound heterozygous for two different SLC7A7 variants.

The LPI urea cycle defect interacts with arginine-dependent nitric oxide synthesis. Intracellular arginine trapping elevates NO production, which may mediate pulmonary, renal, and immune manifestations independently of the systemic amino acid deficiency — suggesting that treatment targeting only hyperammonemia may be insufficient to prevent end-organ damage.

The NFIA-AS2 gene encodes a long non-coding RNA¹¹ long non-coding RNA
lncRNAs regulate gene expression without being translated into proteins, often controlling nearby genes through various mechanisms that regulates the NFIA transcription factor, which plays a crucial role in determining whether hematopoietic stem cells become red blood cells or white blood cells. This SNP, rs1572312, was discovered through a genome-wide association study²² genome-wide association study
GWAS: unbiased screen of the entire genome to identify genetic variants associated with a trait of elite Russian endurance athletes and represents one of the most statistically significant genetic markers for endurance performance yet identified.

The C allele at this position dramatically increases the likelihood of elite endurance athlete status. Among Olympic medalists in endurance events, 100% carried at least one C allele, with the CC genotype reaching 100% frequency — compared to just 78.6% in the general Russian population. This makes it one of the strongest genetic predictors of endurance capacity discovered to date.

The Mechanism

NFIA-AS2 is an antisense RNA³³ antisense RNA
Antisense RNAs are transcribed from the opposite strand of a gene and can regulate that gene's expression through various mechanisms positioned within the first intron of the NFIA gene. By regulating NFIA expression, it influences a critical developmental decision: the choice between erythroid (red blood cell) and granulocytic (white blood cell) lineages during hematopoiesis⁴⁴ hematopoiesis
Blood cell formation from hematopoietic stem cells in the bone marrow.

When NFIA is upregulated⁵⁵ NFIA is upregulated
Research shows NFIA is markedly upregulated in erythroid cells while suppressed in granulocytic cells, it accelerates erythropoiesis — the production of red blood cells — while simultaneously suppressing granulopoiesis. This shifts the balance toward greater red blood cell production. NFIA also controls beta-globin expression⁶⁶ controls beta-globin expression
NFIA regulates the developmental switch from fetal to adult hemoglobin and the transition from fetal to adult hemoglobin, ensuring efficient oxygen transport in adult erythrocytes.

The rs1572312 variant sits in an intron of this regulatory RNA, likely affecting either its expression level, stability, or regulatory activity. The C allele appears to enhance the pro-erythropoietic signal, leading to higher baseline red blood cell production, increased hemoglobin mass, and greater oxygen-carrying capacity — all critical determinants of endurance performance.

The Evidence

The initial GWAS⁷⁷ initial GWAS
Ahmetov II et al. Genome-wide association study identifies three novel genetic markers associated with elite endurance performance. Biol Sport, 2015 examined 1,140,419 SNPs in 80 elite Russian endurance athletes (Olympic-level competitors in cross-country skiing, rowing, and long-distance running) and validated findings in 218 endurance athletes versus 1,789 controls across Russian and European populations. The C allele frequency was 95.5% in elite endurance athletes compared to 89.8% in non-elite endurance athletes (P = 0.026), 88.8% in Russian controls (P = 0.007), 90.6% in European controls (P = 0.020), and 86.2% in power athletes (P = 0.0005).

The most striking finding: all 20 Olympic medalists in the study carried the CC genotype (100% vs 78.6% in controls, P = 0.021). No other genetic variant in exercise genomics has shown such strong association with elite status.

A follow-up study in 238 well-trained athletes⁸⁸ follow-up study in 238 well-trained athletes
Malczewska-Lenczowska J et al. HIF-1α and NFIA-AS2 polymorphisms as potential determinants of total hemoglobin mass in endurance athletes. J Strength Cond Res, 2022 examined the physiological mechanism. Athletes with the CC genotype had significantly higher: - Total hemoglobin mass (tHbmass) in female athletes and cyclists - Plasma volume and blood volume in cyclists - Erythrocyte volume in male athletes and cyclists - Aerobic performance measures in male cyclists

The genotype distribution varied by sport: male cyclists showed substantially higher A allele frequency compared to rowers and distance runners, suggesting different optimal genetic profiles for different endurance disciplines.

Practical Actions

Total hemoglobin mass is one of the strongest physiological determinants of VO2max⁹⁹ VO2max
Maximal oxygen uptake, the gold standard measure of aerobic fitness, explaining 60-80% of individual variation in elite athletes. The NFIA-AS2 CC genotype provides a fundamental advantage in oxygen transport capacity through increased red blood cell production.

For individuals with the CC genotype, this translates to naturally higher hemoglobin levels and potentially superior response to endurance training and altitude exposure. For those with CA or AA genotypes, the lower baseline hemoglobin mass can be partially compensated through strategic training approaches: altitude training (natural or simulated), heat acclimatization protocols that stimulate plasma volume expansion, and ensuring optimal iron status to maximize the efficiency of existing erythropoiesis.

Regardless of genotype, regular monitoring of hemoglobin levels¹⁰¹⁰ monitoring of hemoglobin levels
Complete blood count (CBC) with hemoglobin, hematocrit, and red blood cell count and iron status¹¹¹¹ iron status
Serum ferritin, iron, total iron binding capacity, and transferrin saturation is essential for endurance athletes, as the demands of high-volume training can deplete iron stores and suppress erythropoiesis even in genetically advantaged individuals.

Interactions

NFIA-AS2 rs1572312 operates in the same biological pathway as other endurance-related variants but at a different level. While ACTN3 R577X¹²¹² ACTN3 R577X
rs1815739 affects muscle fiber type composition and PPARGC1A Gly482Ser¹³¹³ PPARGC1A Gly482Ser
rs8192678 influences mitochondrial biogenesis, NFIA-AS2 controls the oxygen transport system itself — the supply side of the aerobic equation.

These variants likely show additive or synergistic effects: having favorable alleles at all three loci would combine efficient muscle contractile properties (ACTN3 XX for endurance), abundant mitochondria (PPARGC1A GG), and superior oxygen delivery (NFIA-AS2 CC). Conversely, unfavorable combinations might create mismatches — abundant mitochondria but insufficient oxygen delivery, or high oxygen-carrying capacity but poor muscular oxidative capacity.

The variant may also interact with altitude training response. Individuals with the CC genotype may experience greater hemoglobin mass increases during altitude exposure due to enhanced baseline erythropoietic capacity, though this hypothesis requires direct experimental testing.

Every time a cell divides, its telomeres — the protective caps on chromosome ends — lose a small amount of DNA. Telomerase, the enzyme responsible for rebuilding these caps, depends on two components working in concert: TERT (the protein catalytic subunit) and TERC (the RNA template that specifies the sequence to be added). The rs16847897 variant sits at the 3q26 locus near TERC, within an approximately 87-kilobase region showing one of the strongest genetic associations with leukocyte telomere length discovered in human populations.

The Mechanism

rs16847897 lies within an intron of LRRC31, a neighboring gene, but its biological significance is attributed to its proximity to and likely regulatory influence on TERC expression. Like the nearby rs12696304, a second well-studied TERC locus variant in weak linkage disequilibrium, rs16847897 does not alter the TERC RNA sequence itself — TERC functions as a non-coding RNA, not a protein. Instead, the C risk allele likely reduces the efficiency of TERC transcription or processing, leaving telomerase with less of its RNA template component. With reduced template availability, the enzyme extends telomeres less efficiently, and chromosome ends shorten faster with each cell division.

The additive nature of the association — each copy of the C allele independently reduces telomere length — is consistent with a haploinsufficiency model: even one reduced-function allele measurably diminishes the telomere-maintenance buffer.

The Evidence

The landmark association was established in a genome-wide study of 3,554 individuals from the Nurses' Health Study and PLCO Cancer Screening Trial¹¹ genome-wide study of 3,554 individuals from the Nurses' Health Study and PLCO Cancer Screening Trial
Prescott J et al. GWAS of relative telomere length. PLOS One 2011. The rs16847897 C allele showed a per-allele beta of −0.03 for log relative telomere length (P = 3.0×10⁻³ in the discovery cohort), rising to a meta-analytic P = 1.6×10⁻¹³ when combined with published GWAS data — with virtually no between-study heterogeneity (I² = 0.00).

Replication came from a study of 4,016 Chinese Han individuals²² study of 4,016 Chinese Han individuals
Shen Q et al. Common variants near TERC associated with leukocyte TL in Chinese Han. Eur J Hum Genet 2011, which confirmed that each C allele was associated with 0.031 T/S units shorter mean telomere length — equivalent to approximately 4 years of average age-related telomere attrition. Notably, in the Chinese population the C allele is common (frequency ~0.61), making CC homozygotes the plurality rather than the rare case, yet the directionality and magnitude of effect were consistent with European findings.

A subsequent metabolic study found the CC homozygous genotype associated with significantly shorter leukocyte telomere length (OR 1.6, p = 0.004)³³ CC homozygous genotype associated with significantly shorter leukocyte telomere length (OR 1.6, p = 0.004)
Al Khaldi R et al. Associations of TERC SNPs with LTL and T2DM risk. PLOS One 2015, lower TERT protein levels, higher BMI, larger waist circumference, and reduced adiponectin — a constellation of findings linking telomere biology to metabolic health. When CC genotype at rs16847897 was combined with the GG risk genotype at rs12696304, risk for type 2 diabetes increased significantly (OR 1.7, p = 0.004), suggesting additive effects of TERC locus variants on metabolic outcomes.

A haplotype study of 2,353 participants⁴⁴ haplotype study of 2,353 participants
Maubaret CG et al. TERC and OBFC1 haplotypes associated with LTL and CHD risk. PLOS One 2013 found a TERC haplotype carrying rs16847897-C was associated with a lower risk of coronary heart disease (OR 0.86) and type 2 diabetes (OR 0.74), without measurable effect on telomere length — suggesting the TERC locus may influence cardiovascular disease through telomere-independent mechanisms as well.

Practical Actions

Because C alleles reduce telomere maintenance capacity at the TERC template level, the key practical goal for carriers is to minimize additional insults to telomere integrity. Oxidative stress — from tobacco smoke, chronic inflammation, or radiation — damages the guanine-rich telomeric repeat sequence (TTAGGG) preferentially, and reduced TERC activity means less repair capacity to compensate. Supporting antioxidant defenses and reducing inflammatory load directly addresses the mechanism of telomere attrition in C allele carriers.

Metabolic health management is particularly relevant: the CC genotype has been independently linked to higher BMI, central adiposity, and T2DM risk, suggesting that telomere biology and metabolic regulation intersect at the TERC locus through mechanisms that go beyond telomere length itself.

Interactions

rs16847897 is situated within the same TERC locus as rs12696304, the better-studied TERC telomere length variant. The two SNPs are in weak linkage disequilibrium and may tag partially overlapping regulatory signals. Individuals carrying risk alleles at both positions may experience compounded telomere shortening, and the T2DM data (OR 1.7 for the combined GG×CC genotype) support additive effects.

At the pathway level, rs16847897 interacts with TERT rs2736100 (the catalytic subunit of telomerase) to set overall telomerase activity. A Ugandan cohort study of 736 HIV+ children and adolescents⁵⁵ Ugandan cohort study of 736 HIV+ children and adolescents
Kalungi A et al. TERT rs2736100 and TERC rs16847897 moderate IMD-TL attrition. BMC Med Genomics 2021 found that TERC rs16847897 CC genotype significantly moderated the association between internalizing mental disorders (depression, anxiety, PTSD) and accelerated telomere attrition over 12 months (p = 0.012), with the strongest effects in CC carriers — paralleling similar moderation findings for TERT rs2736100 in the same cohort. This suggests that the combined state of both telomerase genes influences how psychological stress translates into cellular aging.

A genetic variant in the ALOX5AP gene — encoding the 5-lipoxygenase-activating protein (FLAP) — tags a risk haplotype that has been linked to myocardial infarction and stroke across multiple European cohorts. FLAP is the membrane scaffold that enables 5-lipoxygenase (5-LOX) to process arachidonic acid into pro-inflammatory leukotrienes, particularly leukotriene B4 (LTB4)¹¹ leukotriene B4 (LTB4)
a potent lipid mediator that recruits neutrophils, activates macrophages, and promotes atherosclerotic plaque formation. Without FLAP, 5-LOX cannot dock on the nuclear membrane and remains catalytically inactive.

The Mechanism

rs17222842 is an intronic tag SNP — a marker, not a functional mutation — that travels with the four-SNP HapB haplotype (rs17216473A–rs10507391A–rs9315050A–rs17222842*G*). Carriers of this haplotype show evidence of increased leukotriene pathway activity, which promotes:

• Macrophage activation and foam-cell formation in arterial plaques
• Endothelial dysfunction via LTB4-driven oxidative stress
• Platelet aggregation and vasospasm through cysteinyl leukotrienes
• Systemic low-grade inflammation measurable as elevated hs-CRP

The minor A allele at rs17222842 is absent from HapB and correlates with reduced haplotype burden — i.e., the A allele tags the absence of the full risk haplotype. Carriers of the A allele therefore represent a genetically lower-risk subgroup.

The Evidence

The story begins with the landmark Helgadottir et al. 2004 Nature Genetics paper²² Helgadottir et al. 2004 Nature Genetics paper
"The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke", which identified ALOX5AP haplotypes as conferring approximately twice the risk of MI and stroke in Icelandic and British populations. A 2005 Scottish replication study³³ 2005 Scottish replication study
Helgadottir A et al., Am J Hum Genet, 2005 confirmed HapA's stroke association (RR 1.36, P=0.007) in 450 stroke patients vs 710 controls.

For HapB specifically — the haplotype defined by the rs17222842 G allele — evidence has accumulated across multiple cohorts:

• A 2010 meta-analysis by Huang et al.⁴⁴ 2010 meta-analysis by Huang et al.
  Arch Med Res, 2010 found HapB associated with CHD (OR 1.33, 95% CI 1.10–1.62) and rs17222842 alone showed a marginal CHD association (OR 1.17, 95% CI 1.00–1.36) across studies published through January 2010.
• An angiography-based Italian study of 1,431 patients (Girelli et al. 2007)⁵⁵ angiography-based Italian study of 1,431 patients (Girelli et al. 2007)
  Eur J Hum Genet, 2007 found HapB associated with angiographically confirmed CAD (OR 1.67, 95% CI 1.04–2.67, P=0.032).
• In a cohort of 1,817 familial hypercholesterolemia patients (van der Net et al. 2009)⁶⁶ cohort of 1,817 familial hypercholesterolemia patients (van der Net et al. 2009)
  Atherosclerosis, 2009, HapB conferred HR 1.48 (95% CI 1.17–1.89, P=0.001) for CHD — rising to HR 1.82 in the highest-LDL subgroup, suggesting synergy between leukotriene-driven inflammation and lipid burden.
• A US European-American study of 1,000 participants (Tsai et al. 2009)⁷⁷ US European-American study of 1,000 participants (Tsai et al. 2009)
  Atherosclerosis, 2009 reported HapB associated with premature CAD with an adjusted OR of 2.05.

Importantly, the A allele itself shows a directly protective signal: Oosterveer et al. 2009⁸⁸ Oosterveer et al. 2009 found the A allele at rs17222842 was protective against tendon xanthomas in 945 FH patients (OR 0.62, 95% CI 0.43–0.90, P=0.01), consistent with reduced inflammatory drive.

However, effect sizes vary across populations and some prospective studies in non-European cohorts found no association, highlighting that this is a moderate-evidence haplotype marker rather than a high-penetrance causal variant.

Practical Actions

For individuals carrying GG (the common genotype, without the protective A allele), strategies that reduce leukotriene-driven inflammation are most relevant:

• Omega-3 fatty acids (EPA/DHA): EPA competes with arachidonic acid for 5-LOX, directly reducing the substrate available for leukotriene synthesis
• Monitoring cardiovascular inflammatory biomarkers (hs-CRP, Lp-PLA2): more informative than standard lipid panels for leukotriene-pathway risk
• Targeted anti-inflammatory diet: reducing dietary arachidonic acid (red meat, high-fat dairy) limits leukotriene precursor availability

For A allele carriers (AG or AA), the protective signal at this locus is reassuring, though it does not override other cardiovascular risk factors.

Interactions

rs17222842 is one of four tag SNPs constituting the ALOX5AP HapB haplotype. The full haplotype is defined by: rs17216473 (A allele) + rs10507391 (A allele) + rs9315050 (A allele) + rs17222842 (G allele). Haplotype carriers who also carry high-LDL variants (e.g. LDLR, APOB, PCSK9) face compounded risk — the Oosterveer/van der Net FH cohorts showed the strongest effects in high-LDL subgroups, suggesting leukotriene- driven inflammation and lipid accumulation act synergistically in plaque development. Interaction with COX-2 (PTGS2) pathway variants may also modulate net eicosanoid balance in favor of or against resolution of arterial inflammation.

FADS1 (Fatty Acid Desaturase 1) encodes the delta-5 desaturase enzyme that converts short-chain omega-3 fatty acids¹¹ ALA (alpha-linolenic acid) is the plant-derived omega-3 found in flax, chia, and walnuts into the longer-chain EPA and DHA²² EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are the biologically active omega-3s essential for brain function and inflammation control that your brain and body actually use.

The Mechanism

The rs174547 variant sits in intron 9 of FADS1. The C allele (minor allele in most populations) is associated with lower delta-5 desaturase activity, meaning reduced ability to convert plant-derived ALA into the active EPA and DHA forms. Carriers of the C allele have higher levels of the omega-6 precursor linoleic acid and lower levels of arachidonic acid, EPA, and DHA.

Notably, the C allele frequency varies dramatically across populations — from just 6% in Africans to 46% in East Asians — reflecting different evolutionary pressures related to diet.

The Evidence

A landmark GWAS by Tanaka et al.³³ landmark GWAS by Tanaka et al.
Tanaka et al. Genome-wide association study of plasma polyunsaturated fatty acids in the InCHIANTI Study. PLoS Genet, 2009 in 1,075 participants identified the FADS1 locus as the strongest genetic determinant of plasma PUFA levels, explaining 18.6% of variance in arachidonic acid levels.

A meta-analysis by Chen et al.⁴⁴ meta-analysis by Chen et al.
Chen et al. Association between FADS1 rs174547 and levels of long-chain PUFA: a meta-analysis. Br J Nutr, 2021 confirmed that C allele carriers have significantly lower levels of long-chain PUFAs across multiple populations.

Why This Matters

Not everyone converts plant omega-3s efficiently. If you're a poor converter (CC genotype), eating flax seeds won't meaningfully raise your EPA/DHA levels. You need to get these directly from fish or supplements.

This is especially relevant for vegetarians and vegans⁵⁵ Algae-based EPA/DHA supplements offer a plant-based alternative to fish oil for poor converters who rely on plant sources for omega-3s.

Interactions

FADS1 function interacts with dietary patterns. If you also carry TCF7L2 risk alleles (rs7903146), getting adequate omega-3s from direct sources (fish, supplements) becomes even more important for cardiovascular protection.